Geisinger Medical Laboratories Test Catalog
TYPE AND SCREEN |
||
ORDERING INFORMATION: |
Geisinger Epic Procedure Code: LAB3207 Geisinger Epic ID: 15475 | |
SPECIMEN COLLECTION |
||
Specimen type: |
Whole Blood | |
Preferred collection container: |
||
Alternate Collection Container: |
Lavender-top (K2 EDTA) microcollection tube
|
|
Specimen required: |
6 mL whole blood or 3 full EDTA microcollection tubes. | |
Special notes: |
Add-on testing is not permitted. Specimen must be labeled with patient's first and last name, medical record number or some unique other identifier (e.g.,billing number, NOT date of birth). Date of collection and phlebotomist identification (full name or tech ID) must be available.
|
|
SPECIMEN PROCESSING |
||
Specimen processing instructions: |
Do not centrifuge or aliquot. | |
Transport temperature: |
Preferred specimen: Room temperature (less than 24 hours). If greater than 24 hours, specimen must be stored and transported at 2-8° C. | |
Specimen stability: |
Specimen must be less than 3 days old for testing. | |
Rejection criteria: |
Tube containing gel separator. Incomplete label ID (see collection notes). | |
TEST DETAILS |
||
Additional information: |
Antibody-positive specimens will be worked up to the extent necessary to identify the antibody. Geisinger Health System workflow is to order type and screen followed by a prepare and transfuse order in Epic if blood products are needed. | |
CPT code(s): |
86900, 86850, 86901 | |
Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
ANTIBODY SCREEN (ABSC) and BLOOD GROUP & TYPE (ABO/RH) | |
Methodology: |
RBC agglutination and/or gel column technology |
|
Synonyms: |
TSC, TYPE, SCREEN, CROSSMATCH
|
|
Clinical significance: |
Type and screen battery must be performed to provide compatible blood. "Type" includes ABO and Rh typing of the patient's red blood cells. "Screen" includes a red blood cell antibody screen, which can detect common clinically significant antibodies to red blood cells. For prenatal patients, the patient's Rh determines if she is a Rhogam candidate, and the antibody screen determines if the mother has any pre-existing IgG alloantibodies that could cross the placenta. | |
Doctoral Director(s:) |
Randin Nelson MD | |
Review Date: | 10/21/2022 |
Performing Locations
Geisinger Wyoming Valley Medical Center